TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31738115

Group type: EXPERIMENTAL
Intervention: Local anesthesia plus 200 IU onabotulinum toxin A
Number of subjects: 64

Group type: COMPARATOR
Intervention: Local anesthesia alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Open label trial with onabotulinum toxin A
Number of subjects: 64
Study: 30811457

Group type: EXPERIMENTAL
Intervention: Surgeons (both male and female)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Female surgeons
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Male surgeons
Number of subjects: 415
Study: 28264720

Group type: EXPERIMENTAL
Intervention: Fidelity oriented learning collaborative
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Continuous quality improvement-oriented learning collaborative
Number of subjects: 32
Study: 26386786

Group type: EXPERIMENTAL
Intervention: Varenicline (1.0 mg twice daily)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Varenicline and Placebo
Number of subjects: 302
Study: 23415877

Group type: COMPARATOR
Intervention: Anodal HD-tDCS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cathodal HD-tDCS
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 18
Study: 17211114

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (60% to 80% intensity of maximal heart rate for 25 minutes, 3 times per week, for 6 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no exercise treatment during the research period)
Number of subjects: 26
Study: 12899796

Group type: EXPERIMENTAL
Intervention: Copper ion electrochemistry (CIE) for bleeding due to hemorrhoid
Number of subjects: 202

Group type: COMPARATOR
Intervention: Suppository treatment for bleeding due to hemorrhoid
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Copper ion electrochemistry (CIE) for prolapse of hemorrhoid
Number of subjects: 202

Group type: COMPARATOR
Intervention: Suppository treatment for prolapse of hemorrhoid
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Copper ion electrochemistry (CIE)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control side (routine hemostasis)
Number of subjects: 202
Study: 10810687

Group type: EXPERIMENTAL
Intervention: Absorbable suture anchors
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control shoulders
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 8800890

Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 93
Study: 1310497

Group type: EXPERIMENTAL
Intervention: etanidazole (ETA) unmodified (2 g/m2, 3 times weekly for 17 doses)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: etanidazole (ETA) schedule adjustment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: etanidazole (ETA) individualized dose modification
Number of subjects: 54
Study: 6704011

Group type: EXPERIMENTAL
Intervention: Nasolacrimal occlusion (NLO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eyelid closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: No procedures (control)
Number of subjects: 0
Study: 30484720

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (traditional clamp‐crushing method)
Number of subjects: 66
Study: 29018084

Group type: EXPERIMENTAL
Intervention: Oral morphine (0.5 mg/kg)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 154
Study: 25858633

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) training program
Number of subjects: 154

Group type: COMPARATOR
Intervention: Advice approach (Control group)
Number of subjects: 154
Study: 23992206

Group type: EXPERIMENTAL
Intervention: Mini-invasive technique (Group B)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard laparoscopic myomectomy (Group A)
Number of subjects: 170
Study: 20940337

Group type: EXPERIMENTAL
Intervention: Intravenous insulin (5 U)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin (10 U)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Inhaled Technosphere insulin (25, 50, and 100 U)
Number of subjects: 16
Study: 19471136

Group type: EXPERIMENTAL
Intervention: Depressive symptoms and social support
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Clinical and functional characteristics of disease status
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Clinical and functional characteristics
Number of subjects: 695
Study: 17344588

Group type: EXPERIMENTAL
Intervention: FK506 (tacrolimus) group, n=43
Number of subjects: 73
Study: 15118650

Group type: EXPERIMENTAL
Intervention: Prenatal zinc supplementation (25 mg zinc)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Prenatal supplementation without zinc (control group)
Number of subjects: 242
Study: 11913306

Group type: EXPERIMENTAL
Intervention: Baking Soda Gum (AHDC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-baking soda placebo gum
Number of subjects: 48
Study: 9559732

Group type: EXPERIMENTAL
Intervention: Nonpreserved ketorolac tromethamine 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 7884791

Group type: EXPERIMENTAL
Intervention: Moexipril monotherapy (7.5, 15, or 30 mg once daily)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Moexipril combined with hydrochlorothiazide (15-30 mg daily with 12.5 mg hydrochlorothiazide)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Moexipril monotherapy
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Moexipril combined with hydrochlorothiazide
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Adverse side effects of moexipril
Number of subjects: 281
Study: 2905253

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 30706520

Group type: EXPERIMENTAL
Intervention: Active strategy for the diagnosis and anticoagulant treatment of pulmonary embolism (PE)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Usual care (standard care without any diagnostic test for diagnosing PE)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Active strategy for the diagnosis and anticoagulant treatment of PE
Number of subjects: 746
Study: 28260202

Group type: EXPERIMENTAL
Intervention: High hypoxia (HH: FiO2 = 0.13)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normoxia (NORM: FiO2 = 0.21)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (MH: FiO2 = 0.16)
Number of subjects: 12
Study: 26378492

Group type: EXPERIMENTAL
Intervention: Physical activity guideline attainment at 6 weeks posthospitalization
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Physical activity guideline attainment at 4 months
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Physical activity guideline attainment at 12 months
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Walking behavior
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Moderate-intensity PA
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity PA
Number of subjects: 136
Study: 23210470

Group type: EXPERIMENTAL
Intervention: Acu‐TENS (application of TENS on BL13, Feishu)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo‐TENS (similar to Acu‐TENS but without electrical output)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Acu‐TENS
Number of subjects: 18
Study: 21596605

Group type: EXPERIMENTAL
Intervention: Allostatic load score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HbA(1c)
Number of subjects: 0
Study: 18000659

Group type: EXPERIMENTAL
Intervention: Erlotinib with ketoconazole (CYP3A4 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 0
Study: 17010056

Group type: EXPERIMENTAL
Intervention: Selective estrogen receptor modifiers (tamoxifen, raloxifene)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 14634811

Group type: EXPERIMENTAL
Intervention: Mapping up with right and down with left
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulus-set position manipulation
Number of subjects: 0
Study: 11128246

Group type: EXPERIMENTAL
Intervention: Gabapentin monotherapy after discontinuation of carbamazepine (CBZ)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Other antiepileptic medications
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Discontinuation of carbamazepine (CBZ)
Number of subjects: 275
Study: 9094871

Group type: EXPERIMENTAL
Intervention: High-sucrose diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-sucrose diet
Number of subjects: 42
Study: 1493661

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC) 1 g b.i.d
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2859304

Group type: EXPERIMENTAL
Intervention: Rapidly eliminated hypnotics (triazolam, midazolam, lormetazepam)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slowly eliminated hypnotics (flurazepam, quazepam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31345078

Group type: EXPERIMENTAL
Intervention: Nonenhanced multidetector computed tomography (MDCT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (20 subjects)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endovascular stent placement (ESP)
Number of subjects: 20
Study: 29490310

Group type: EXPERIMENTAL
Intervention: Nondiabetic patients with peri-implantitis
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Diabetic patients with peri-implantitis
Number of subjects: 171

Group type: COMPARATOR
Intervention: Nondiabetic patients without peri-implantitis
Number of subjects: 171

Group type: COMPARATOR
Intervention: Diabetic patients without peri-implantitis
Number of subjects: 171
Study: 28327683

Group type: EXPERIMENTAL
Intervention: Oblique incision
Number of subjects: 146

Group type: COMPARATOR
Intervention: Vertical incision
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study: 24472084

Group type: EXPERIMENTAL
Intervention: Compound betamethasone 7 mg intramuscular injection (i.m.) once
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diclofenac sodium 75 mg twice a day for 7 days
Number of subjects: 60
Study: 22995882

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 88
Study: 19962735

Group type: EXPERIMENTAL
Intervention: AlloDerm closure
Number of subjects: 20

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 20
Study: 17907112

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) infusion
Number of subjects: 25

Group type: COMPARATOR
Intervention: No GIK infusion (Control)
Number of subjects: 25
Study: 16214489

Group type: EXPERIMENTAL
Intervention: Patella alta
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal patellar position
Number of subjects: 27
Study: 12405236

Group type: EXPERIMENTAL
Intervention: Educational intervention program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 60
Study: 10486787

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 1157

Group type: COMPARATOR
Intervention: HRT
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Estrogen
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Unopposed Estrogen
Number of subjects: 1157
Study: 8609825

Group type: EXPERIMENTAL
Intervention: 10% carbohydrate (CHO) drink without prior CHO-loading (NLC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water placebo after CHO-loading (CLP)
Number of subjects: 16
Study: 2025478

Group type: EXPERIMENTAL
Intervention: Ketanserin 10 mg i.v. followed by an infusion of 0.075 mg kg‐1 h‐1
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 6894644

Group type: EXPERIMENTAL
Intervention: Electromyographic feedback during 20 minutes of isometric exercises
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional physical therapy (20 minutes of isometric exercises)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Electromyographic feedback
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 26
Study: 30257898

Group type: EXPERIMENTAL
Intervention: Ceftaroline disk diffusion with 30-μg disks
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Ceftaroline MIC of 2 μg/ml
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Ceftaroline MIC of 1 μg/ml
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Ceftaroline MIC of ≥4 μg/ml
Number of subjects: 158
Study: 28887690

Group type: EXPERIMENTAL
Intervention: ACD (anterior cervical discectomy without fusion)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: ACDF (anterior cervical discectomy with fusion by stand-alone cage)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: ACDA (anterior cervical discectomy with arthroplasty)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 142
Study: 25729196

Group type: EXPERIMENTAL
Intervention: Spinal decompression therapy (SDTG, n=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: General traction therapy (GTTG, n=15)
Number of subjects: 30
Study: 23187955

Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt (200g per day for 9 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional yoghurt (200g per day for 9 weeks)
Number of subjects: 70
Study: 21456017

Group type: EXPERIMENTAL
Intervention: Lapatinib monotherapy
Number of subjects: 138
Study: 18679072

Group type: COMPARATOR
Intervention: PEG‐IFN monotherapy (n=64)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PEG‐IFN + RBV (n=57)
Number of subjects: 210

Group type: COMPARATOR
Intervention: PEG‐IFN + RBV (n=42)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PEG‐IFN + RBV + amantadine (n=47)
Number of subjects: 210
Study: 16531440

Group type: EXPERIMENTAL
Intervention: tranexamic acid 10 mg kg(‐1) i.v. just before tourniquet deflation and 3 h later
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: epsilon‐aminocaproic acid 100 mg kg(‐1) before tourniquet deflation followed by continuous perfusion (1 g h(‐1)) during 3 h
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: tranexamic acid and epsilon‐aminocaproic acid
Number of subjects: 127
Study: 11966791

Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice a day for 10 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice a day for 14 days
Number of subjects: 120
Study: 9617328

Group type: EXPERIMENTAL
Intervention: UFT with OK-432
Number of subjects: 0

Group type: COMPARATOR
Intervention: UFT
Number of subjects: 0
Study: 7593775

Group type: EXPERIMENTAL
Intervention: Polarized light photography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polarized light photography with precise framing and mapping
Number of subjects: 0
Study: 2469654

Group type: EXPERIMENTAL
Intervention: HES 200/0.5 10%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextran 40 10%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrolyte solution
Number of subjects: 0
Study: 162923

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside (20 mg/kg of body weight, intravenously every 24 hr for seven days in an 8-hr infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside
Number of subjects: 20
Study: 7362724

Group type: EXPERIMENTAL
Intervention: Suxamethonium 1.0 mg kg‐1
Number of subjects: 2

Group type: COMPARATOR
Intervention: Thiopentone, pancuronium bromide
Number of subjects: 2
Study: 30694011

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 116
Study: 29044764

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic BP target of <120 mmHg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard treatment (systolic BP target of <140 mmHg)
Number of subjects: 9361
Study: 26867157

Group type: EXPERIMENTAL
Intervention: Panitumumab added to docetaxel-based chemotherapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Docetaxel-based chemotherapy alone
Number of subjects: 77
Study: 25116230

Group type: EXPERIMENTAL
Intervention: Experimental formula (EF) with added milk fat globule membrane (MFGM)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Breast-fed reference (BFR)
Number of subjects: 240
Study: 21936758

Group type: EXPERIMENTAL
Intervention: Family-centred practice (FCP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual practice (UP)
Number of subjects: 20
Study: 19761536

Group type: EXPERIMENTAL
Intervention: Cough-reflex sensitivity evaluated using log concentration of capsaicin causing five or more coughs (log C(5)) in COPD patients.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cough-reflex sensitivity evaluated using log concentration of capsaicin causing five or more coughs (log C(5)) in control group.
Number of subjects: 45
Study: 17992451

Group type: COMPARATOR
Intervention: UVB monotherapy
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: UVB + bergamot oil (UVBB)
Number of subjects: 193
Study: 15990127

Group type: EXPERIMENTAL
Intervention: Pharmacist-managed hypertension clinic
Number of subjects: 51
Study: 12010156

Group type: EXPERIMENTAL
Intervention: Non-submerged ITI implants
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: First 498 implants after at least five years of functional loading
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: 12 mm long implants
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: 10 mm long implants
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: 8 mm long implants
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Mandibular implants
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Maxillary implants
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Patients with both maxillary and mandibular prostheses
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Implants supporting maxillary overdentures retained by Dolder bars
Number of subjects: 233
Study: 10458050

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7821124

Group type: EXPERIMENTAL
Intervention: Loxiglumide (CCK-receptor antagonist)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 26
Study: 1695053

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMW heparin) given once daily
Number of subjects: 96

Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMW heparin)
Number of subjects: 96
Study: 76748

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (E.C.T.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simulated E.C.T.
Number of subjects: 40
Study: 31132157

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28982045

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 212
Study: 26476943

Group type: EXPERIMENTAL
Intervention: Higher plane of milk replacer nutrition (28% CP, 20% fat) with human visitation (A1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Higher plane of milk replacer nutrition (28% CP, 20% fat) without human visitation (A0)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional milk replacer (20% CP, 20% fat) with human visitation (C1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional milk replacer (20% CP, 20% fat) without human visitation (C0)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Higher plane of milk replacer nutrition (A0 and A1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Human visitation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Higher plane of nutrition (A0 and A1)
Number of subjects: 36
Study: 23775260

Group type: EXPERIMENTAL
Intervention: Riociguat 2 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 21255856

Group type: EXPERIMENTAL
Intervention: Small-sided soccer games on badminton court (6.1×13.4 m)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Small-sided soccer games on volleyball court (9×18 m)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Small-sided soccer games on basketball court (14.2×26.5 m)
Number of subjects: 12
Study: 20037706

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone hexacetonide combined with 15 mCi Samarium(153)‐particulate hydroxyapatite (Sm/TH group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 40 mg triamcinolone hexacetonide alone (TH group)
Number of subjects: 58
Study: 17696821

Group type: EXPERIMENTAL
Intervention: Biologic drugs
Number of subjects: 0
Study: 15151687

Group type: EXPERIMENTAL
Intervention: Oral health education programme (yearly 1-h instruction)
Number of subjects: 3291

Group type: COMPARATOR
Intervention: Control group (676 12-year-old children, no intervention)
Number of subjects: 3291
Study: 12359855

Group type: EXPERIMENTAL
Intervention: Zoledronic acid at 4 mg
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Zoledronic acid at 8/4 mg
Number of subjects: 643

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Zoledronic acid at 4 mg and 8/4 mg
Number of subjects: 643